Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 10, Number 5—May 2004

Research

Enzyme-Linked Immunosorbent Assay and Serologic Responses to Pneumocystis jiroveci

Kieran R. Daly*Comments to Author , Judy Koch*, Linda Levin*, and Peter D. Walzer*
Author affiliations: *University of Cincinnati College of Medicine, Cincinnati, Ohio, USA; ‡Veterans Affairs Medical Center, Cincinnati, Ohio, USA

Main Article

Table 2

Adjusted odds ratios (95% CI) measuring the associations between Western blot reactivity and ELISA values (25–75 percentile increase) among 189 study participantsa,b

ELISA Blood donor, n = 95 (95% CI) PCP+, n = 33 (95% CI) PCP–, n = 61 (95% CI) HIV, n = 94 (95% CI)
1
1.1 (0.9 to 1.4)
5.1 (2.2 to 11.8)
1.4 (0.8 to 2.6)
2.7 (1.2 to 5.8)
2
1.1 (0.9 to 1.4)
20.4 (6.4 to 65.1)
3.6 (2.0 to 6.6)
8.6 (4.4 to 16.9)
3 1.0 (0.9 to 1.1) 11.6 (3.6 to 37.9) 7.4 (3.6 to 15.1) 9.3 (4.7 to 18.5)

aCI, confidence interval; ELISA, enzyme-linked immunosorbent assay; PCP, Pneumocystis pneumonia.
bOdds ratios were obtained by using logistic regression. Positive associations were found between Western blot reactivity and increasing ELISA. Based on 95% confidence intervals, the odds of Western blot reactivity were significantly related (p < 0.05) to increasing ELISA 1, 2, and 3 among PCP+ patients and HIV patients across all antigens. For PCP– patients this result was true for ELISA 2 and 3 only. No significant results were found for the blood donor group.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO